Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor.

Bryce A, Ryan CJ.

Clin Pharmacol Ther. 2012 Jan;91(1):101-8. doi: 10.1038/clpt.2011.275. Epub 2011 Nov 30. Review.

PMID:
22130117
2.

New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.

Sharifi N.

Expert Opin Investig Drugs. 2010 Jul;19(7):837-46. doi: 10.1517/13543784.2010.494178. Review.

PMID:
20524793
3.

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

Rehman Y, Rosenberg JE.

Drug Des Devel Ther. 2012;6:13-8. doi: 10.2147/DDDT.S15850. Epub 2012 Jan 16. Review.

4.

The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.

Courtney KD, Taplin ME.

Curr Opin Oncol. 2012 May;24(3):272-7. doi: 10.1097/CCO.0b013e328351059d. Review.

PMID:
22327837
5.

Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.

Vis AN, Schröder FH.

BJU Int. 2009 Aug;104(4):438-48. doi: 10.1111/j.1464-410X.2009.08695.x. Epub 2009 Jun 24. Review.

6.

Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function.

Sharifi N.

Anticancer Agents Med Chem. 2009 Dec;9(10):1046-51. Review.

PMID:
19719456
7.

Agents that target androgen synthesis in castration-resistant prostate cancer.

Ferraldeschi R, de Bono J.

Cancer J. 2013 Jan-Feb;19(1):34-42. doi: 10.1097/PPO.0b013e31827e0b6f. Review.

PMID:
23337755
8.

Novel agents for the management of castration-resistant prostate cancer.

Haddad H, Garcia JA.

Curr Opin Urol. 2012 May;22(3):175-82. doi: 10.1097/MOU.0b013e3283523ba0. Review.

PMID:
22472509
9.

Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.

Salem M, Garcia JA.

Curr Oncol Rep. 2011 Apr;13(2):92-6. doi: 10.1007/s11912-011-0153-4. Review.

PMID:
21243537
10.

Abiraterone acetate: redefining hormone treatment for advanced prostate cancer.

Pezaro CJ, Mukherji D, De Bono JS.

Drug Discov Today. 2012 Mar;17(5-6):221-6. doi: 10.1016/j.drudis.2011.12.012. Epub 2011 Dec 19. Review.

PMID:
22198164
11.

[Abiraterone acetate (AA): current guidelines of prescription of abiraterone].

Boissier E, Loriot Y, Vignot S, Massard C.

Bull Cancer. 2014 Apr;101(4):388-93. doi: 10.1684/bdc.2014.1932. Review. French.

PMID:
24793632
12.

Overcoming castration resistance in prostate cancer.

Tsao CK, Small AC, Galsky MD, Oh WK.

Curr Opin Urol. 2012 May;22(3):167-74. doi: 10.1097/MOU.0b013e3283523b8b. Review.

PMID:
22472508
13.

Abiraterone acetate in castration-resistant prostate cancer.

Iacovelli R, Palazzo A, Procopio G, Gazzaniga P, Cortesi E.

Anticancer Drugs. 2012 Mar;23(3):247-54. doi: 10.1097/CAD.0b013e32834e696c. Review.

PMID:
22123334
14.

Androgen receptor antagonists in castration-resistant prostate cancer.

Rathkopf D, Scher HI.

Cancer J. 2013 Jan-Feb;19(1):43-9. doi: 10.1097/PPO.0b013e318282635a. Review.

15.

Novel strategies in the treatment of castration-resistant prostate cancer (Review).

Marech I, Vacca A, Ranieri G, Gnoni A, Dammacco F.

Int J Oncol. 2012 May;40(5):1313-20. doi: 10.3892/ijo.2012.1364. Epub 2012 Feb 9. Review.

PMID:
22322981
16.

Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.

MacVicar GR, Hussain MH.

Curr Opin Oncol. 2013 May;25(3):252-60. doi: 10.1097/CCO.0b013e32835ff161. Review.

PMID:
23511665
17.

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.

Stein MN, Patel N, Bershadskiy A, Sokoloff A, Singer EA.

Asian J Androl. 2014 May-Jun;16(3):387-400. doi: 10.4103/1008-682X.129133. Review.

18.

[Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].

Neuzillet Y, Flamand V, Lebdai S, Villers A, Lebret T.

Prog Urol. 2013 Oct;23 Suppl 1:S34-43. doi: 10.1016/S1166-7087(13)70044-7. Review. French.

PMID:
24314737
19.

Novel hormonal approaches in prostate cancer.

Friedlander TW, Ryan CJ.

Curr Oncol Rep. 2009 May;11(3):227-34. Review.

PMID:
19336015
20.

Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.

Nguyen MM, Wang Z.

Minerva Urol Nefrol. 2008 Mar;60(1):15-29. Review.

PMID:
18427432
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk